Staff Profile | Faculty of Medical Sciences

Dr Jeremy Palmer

Team Scientist

Email: [email protected]
Telephone: +44 (0) 191 208 5507

Publications

Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyotylainen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Oresic M, Groop L, Yki-Jarvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology 2017, 67(1), 128-136.
Probert PM, Palmer JM, Alhusainy W, Amer AO, Rietjens IMCM, White SA, Jones DE, Wright MC. Progenitor-derived hepatocyte-like (B-13/H) cells metabolise 1′-hydroxyestragole to a genotoxic species via a SULT2B1-dependent mechanism. Toxicology Letters 2016, 243, 98-110.
Dyson JK, Palmer J, Wong LL, Kendrick S, Jones DE. Understanding the importance of pro- and anti-inflammatory cytokines in autoimmune hepatitis. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Boston, MA: John Wiley & Sons, Inc.
Nichols EM, Barbour TD, Kerr H, Pappworth IY, Wong EKS, Palmer J, Sheerin NS, Herbert A, Barlow PN, Pickering MC, Marchbank KJ. FH1-5^(18-20) ameliorates experimental C3 glomerulopathy; generation and testing of a murine version for further pre-clinical experiments. In: 15th European Meeting on Complement in Human Disease 2015. 2015, Uppsala, Sweden: Elsevier.
Palmer J, Liu YL, Day CP, Daly A, Anstee QM. Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
Jopson L, Newton JL, Palmer J, Floudas A, Isaacs J, Qian J, Wilkinson J, Trenell M, Blamire A, Howel D, Jones DE. RITPBC: B-Cell Depleting Therapy (rituximab) as a treatment for fatigue in Primary Biliary Cirrhosis: study protocol for a randomised controlled trial. BMJ Open 2015, 5(8), e007985.
Jopson L, Newton JL, Howel D, Palmer J, Isaacs J, Qian J, Wilkinson J, Blamire A, Floudas A, Jones DE. RITPBC: B-cell depleting therapy (RITUXIMAB) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. In: 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
Floudas A, Griffiths L, Jones D, Knight AM, Palmer JM. Altered B cell populations and cytokine production in primary biliary cirrhosis. In: BSI Congress 2013: Annual Congress of the British-Society-for-Immunology. 2013, Liverpool, England: Wiley-Blackwell Publishing Ltd.
Pells G, Ducker S, Palmer J, Newton J, Jones D, UK-PBC Consortium. Patient Impact of Inflammation in Primary Biliary Cirrhosis (PBC): Inflammatory Cytokine Levels are Elevated but Unrelated to Fatigue Severity. In: British Society of Gastroenterology Annual General Meeting. 2013, Glasgow, UK: BMJ Publishing Group.
Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye 2013, 27(9), 1090-1097.
O'Boyle G, Fox CR, Walden HR, Willet JD, Mavin ER, Hine DW, Palmer JM, Barker CE, Lamb CA, Ali S, Kirby JA. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proceedings of the National Academy of Sciences 2012, 109(12), 4598-4603.
Palmer J, Patanwala I, Henderson E, Day CP, Jones DE. Allo- and auto-antibody responses in ALD as biomarkers of prognosis. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
Jones DEJ, Robe A, Palmer J, Kirby JA. Adoptive transfer of self-PDC reactive T-cells into naive mice induces portal tract and bile duct changes characteristic of primary biliary cirrhosis (PBC). In: 41st Annual Meeting of the European Association for the Study of the Liver. 2006, Vienna, Austria: ELSEVIER SCIENCE BV.
McHugh A, Palmer JM, Yeaman SJ, Jones DEJ. Is PDC-E3BP (protein X) a T-cell autoantigen in primary biliary cirrhosis?. In: Hepatology: 54th Annual Meeting of the American Association for the Study of Liver Disease. 2003, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
Robe AJ, Palmer JM, Kirby JA, Bassendine MF, Jones DEJ. [abstract] Characterisation of liver infiltrating T-cell antigen specificity in a mouse model of primary biliary cirrhosis (PBC). Gut 2002, 50(s2), A116 abstract no. 428.
Palmer JM, Stewart S, Kirby J, Jones D. Breakdown of tolerance is seen to both PDC-E2 and PDC-E3BP, individual antigens in primary biliary cirrhosis, in a mouse model of PDC autoreactivity. In: Hepatology: 53rd Annual Meeting of the Association for the Study of Liver Diseases. 2002, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
Robe A, Palmer J, Kirby J, Jones D. Characterisation of liver infiltrating T-cell antigen specificity in a mouse model of primary biliary cirrhosis (PBC). In: Journal of Hepatology. 2002, Elsevier BV.
Palmer JM, Yeaman SJ, Jones DEJ. Epitope specificity of anti-PDC E1 alpha antibodies in primary biliary cirrhosis (PBC). In: Journal of Hepatology. 2001, Elsevier BV.
Jones DE, Robe AJ, Palmer JM, Kirby JA. Exploration of the immunogenicity of the primary biliary cirrhosis autoantigen pyuvate dehydrogenase complex. Hepatology 2001, 34, 730.
Bassendine MF, Palmer JM, Yeaman SJ, Kirby JA, Jones DEJ. Immunological aspects of chronic cholestatic liver diseases. In "FALK Workshop on Hepatobiliary Diseases: Cholestasis and Gallstones" pp 32-41 Eds. Acalovschi and Paumgartner Pub. Kluwer Academic Publishers<br>(Chapter) 2001.
Robe AJ, Palmer JM, Kirby JA, Jones DE. No role for autoreactive antibody in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex, the autoantigen in primary biliary cirrhosis. In: Hepatology. 2001, John Wiley & Sons, Inc.
Burt AD, Jones DEJ, Palmer JM, Kirby JA, Cruz DeDJ, McCaughan GW, Sedgewick JD, Yeaman SJ, Bassendine MF. Histopathology of experimental autoimmune cholangitis - a mouse model of primary biliary cirrhosis. Journal of Pathology 2000, 190, 3A-3A.
Palmer JM, Doshi M, Kirby JA, Yeaman SJ, Bassendine MF, Jones DEJ. Secretory autoantibodies in primary biliary cirrhosis (PBC). Clinical and Experimental Immunology 2000, 122(3), 423-428.
Robe A, Palmer JM, Yeaman SJ, Jones DEJ. The E3BP (protein X) component of pyruvate dehydrogenase complex (PDC) is not a T-cell autoantigen in primary biliary cirrhosis (PBC). In: JOURNAL OF HEPATOLOGY. 2000.
Jones DE, Robe AJ, Palmer JM, Yeaman SJ, Kirby JA. The role played by gender in breakdown of immune tolerance in experimental autoimmune cholangitis: A mouse model of primary biliary cirrhosis. In: HEPATOLOGY. 2000.
Jones DE, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MA. Bacterial motif DNA as ad adjuvant for the development of autoimmunity in primary biliary cirrhosis (PBC). Gut 1999, 44, TH390.
Palmer JM, Jones DEJ, Quinn J, McHugh A, Yeaman SJ. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology 1999, 30(1), 21-26.
Palmer JM, Kirby JA, Yeaman SJ, Doshi M, Jones DE. Persistence of secretory autoantibodies in PBC patients post-liver transplant: a potential mechanism for disease recurrence?. In: Hepatology. 1999, John Wiley & Sons, Inc.
Jones DE, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MF, Burt AD. The time-course of bile duct lesion development in experimental autoimmune cholangitis (A mouse model of primary biliary cirrhosis -PBC). In: HEPATOLOGY. 1999.
Jones DE, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MF, Burt AD. The time-course of bile duct lesion development in experimental autoimmune cholangitis (a mouse model of primary biliary cirrhosis-PBC). In: HEPATOLOGY. 1999.